ASH 2023 | Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trial
Elizabeth O’Donnell, MD, Massachusetts General Hospital, Boston, MA, presents findings from the SKylaRK trial (NCT04430894) investigating isatuximab in combination with once-weekly carfilzomib, lenalidomide, and dexamethasone to treat newly diagnosed multiple myeloma (NDMM). Using a risk-adapted strategy, patients with high-risk cytogenetics were given more aggressive treatment, resulting in an overall response rate (ORR) of 100% and overall survival (OS) of 95% after a two-year follow-up. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Janssen, BMS, Sanofi; Consultancy: Takeda.
